Clinical Trial Update: Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update indicates that a Phase Ib/II study evaluating QLS1304 in combination with endocrine therapy for advanced ER+/HER2- breast cancer is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• QLS1304

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Advanced ER+/HER2- Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING